Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine

被引:27
作者
Maeda, T. [1 ]
Hosen, N. [2 ,3 ]
Fukushima, K. [1 ]
Tsuboi, A. [4 ]
Morimoto, S. [2 ]
Matsui, T. [1 ]
Sata, H. [1 ]
Fujita, J. [1 ]
Hasegawa, K. [2 ]
Nishida, S. [4 ]
Nakata, J. [5 ]
Nakae, Y. [5 ]
Takashima, S. [5 ]
Nakajima, H. [6 ]
Fujiki, F. [6 ]
Tatsumi, N. [3 ]
Kondo, T. [7 ]
Hino, M. [8 ]
Oji, Y. [3 ]
Oka, Y. [5 ]
Kanakura, Y. [1 ]
Kumanogoh, A. [5 ]
Sugiyama, H. [2 ]
机构
[1] Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, Osaka, Japan
[2] Osaka Univ, Grad Sch Med, Dept Funct Diagnost Sci, Osaka, Japan
[3] Osaka Univ, Grad Sch Med, Dept Canc Stem Cell Biol, Osaka, Japan
[4] Osaka Univ, Grad Sch Med, Dept Canc Immunotherapy, Osaka, Japan
[5] Osaka Univ, Grad Sch Med, Dept Resp Med Allergy & Rheumat Dis, Osaka, Japan
[6] Osaka Univ, Grad Sch Med, Dept Canc Immunol, Osaka, Japan
[7] Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Kyoto, Japan
[8] Osaka City Univ, Grad Sch Med, Dept Hematol & Oncol, Osaka 558, Japan
来源
BLOOD CANCER JOURNAL | 2013年 / 3卷
关键词
MINIMAL RESIDUAL DISEASE; CYTOTOXIC T-LYMPHOCYTES; WT1; EXPRESSION; INDUCTION;
D O I
10.1038/bcj.2013.29
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:e130 / e130
页数:3
相关论文
共 8 条
[1]   Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients [J].
Cilloni, D ;
Gottardi, E ;
De Micheli, D ;
Serra, A ;
Volpe, G ;
Messa, F ;
Rege-Cambrin, G ;
Guerrasio, A ;
Divona, M ;
Lo Coco, F ;
Saglio, G .
LEUKEMIA, 2002, 16 (10) :2115-2121
[2]   WT1 AS A NEW PROGNOSTIC FACTOR AND A NEW MARKER FOR THE DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE-LEUKEMIA [J].
INOUE, K ;
SUGIYAMA, H ;
OGAWA, H ;
NAKAGAWA, M ;
YAMAGAMI, T ;
MIWA, H ;
KITA, K ;
HIRAOKA, A ;
MASAOKA, T ;
NASU, K ;
KYO, T ;
DOHY, H ;
NAKAUCHI, H ;
ISHIDATE, T ;
AKIYAMA, T ;
KISHIMOTO, T .
BLOOD, 1994, 84 (09) :3071-3079
[3]  
MIWA H, 1992, LEUKEMIA, V6, P405
[4]   Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression [J].
Oka, Y ;
Tsuboi, A ;
Taguchi, T ;
Osaki, T ;
Kyo, T ;
Nakajima, H ;
Elisseeva, OA ;
Oji, Y ;
Kawakami, M ;
Ikegame, K ;
Hosen, N ;
Yoshihara, S ;
Wu, F ;
Fujiki, F ;
Murakami, M ;
Masuda, T ;
Nishida, S ;
Shirakata, T ;
Nakatsuka, S ;
Sasaki, A ;
Udaka, K ;
Dohy, H ;
Aozasa, K ;
Noguchi, S ;
Kawase, L ;
Sugiyama, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (38) :13885-13890
[5]   Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies [J].
Rezvani, Katayoun ;
Yong, Agnes S. M. ;
Mielke, Stephan ;
Savani, Bipin N. ;
Musse, Laura ;
Superata, Jeanine ;
Jafarpour, Behnam ;
Boss, Carol ;
Barrett, A. John .
BLOOD, 2008, 111 (01) :236-242
[6]   Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues [J].
Tsuboi, A ;
Oka, Y ;
Udaka, K ;
Murakami, M ;
Masuda, T ;
Nakano, A ;
Nakajima, H ;
Yasukawa, M ;
Hiraki, A ;
Oji, Y ;
Kawakami, M ;
Hosen, N ;
Fujioka, T ;
Wu, F ;
Taniguchi, Y ;
Nishida, S ;
Asada, M ;
Ogawa, H ;
Kawase, I ;
Sugiyama, H .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2002, 51 (11-12) :614-620
[7]   Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease [J].
Tsuboi, A. ;
Oka, Y. ;
Kyo, T. ;
Katayama, Y. ;
Elisseeva, O. A. ;
Kawakami, M. ;
Nishida, S. ;
Morimoto, S. ;
Murao, A. ;
Nakajima, H. ;
Hosen, N. ;
Oji, Y. ;
Sugiyama, H. .
LEUKEMIA, 2012, 26 (06) :1410-1413
[8]   ANTI-LEUKEMIC EFFECT OF GRAFT VERSUS HOST DISEASE IN HUMAN RECIPIENTS OF ALLOGENEIC MARROW GRAFTS [J].
WEIDEN, PL ;
FLOURNOY, N ;
THOMAS, ED ;
PRENTICE, R ;
FEFER, A ;
BUCKNER, CD ;
STORB, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1979, 300 (19) :1068-1073